FDA
-
-
-
-
-
-
-
Immunome Inc. (IMNM) PT Raised to $33 at Stephens
-
-
-
-
-
-
-
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
-
-
-
-
-
-
-
Immunome Inc. (IMNM) and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million
-
-
-
-
-
-
-
Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
-
-
-
-
-
-
-
Immunome (IMNM) Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059
-
-
-
-
-
-
-
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
-
-
-
-
-
-
-
FDA Lifts Clinical Hold on Immunome’s IMM-BCP-01 IND Application for the Treatment of COVID-19
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

